Is There a More Personalized Way to Treat DCIS Breast Cancer?
At the 2014 annual meeting of the San Antonio Breast Cancer Symposium, an important report was shared with the largest breast cancer research meeting in the world.
This report came from Ontario Canada that’s called the Ontario Cohort Report which examined the effectiveness of the Oncotype DX Breast Cancer Assay further.
The Ductal Carcinoma In Situ (DCIS) score from the Oncotype DX Breast Cancer Assay was an independent predictor and an important predictor of biologic predictor of the chance of the cancer recurring within the treated breast.
It’s been suggested that this DCIS score can help breast cancer patients tailor their breast cancer treatment. But what we have used historically to make this breast cancer treatment decision is factor such as the age of the patient, the size of the area of the in situ breast cancer, the grade of the cancer which might determine whether radiation therapy is needed when you have breast conservation.
But could this test be the solution to a More accurate and Personalized Way to Treat DCIS Breast Cancer?
Find out from our Medical Director Dr. Jay Harness in this video.
SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS
http://www.youtube.com/user/drjayharness
VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS
http://www.breastcanceranswers.com/news
SUBMIT A QUESTION
http://www.breastcanceranswers.com/
DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR
http://www.breastcanceranswers.com/
CONNECT WITH US!
Google+: http://bit.ly/16nhEnr
Facebook: https://www.facebook.com/BreastCancerAnswers
Twitter: https://twitter.com/BreastCancerDr
-
Category
No comments found